Pranali Ravikumar
Overview
Explore the profile of Pranali Ravikumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
516
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agarwal S, Aznar M, Rech A, Good C, Kuramitsu S, Da T, et al.
Immunity
. 2023 Sep;
56(10):2388-2407.e9.
PMID: 37776850
Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has achieved tremendous success treating B cell malignancies; however, some patients fail to respond due to poor autologous T cell fitness....
2.
Kalbasi A, Siurala M, Su L, Tariveranmoshabad M, Picton L, Ravikumar P, et al.
Nature
. 2022 Nov;
612(7938):E10.
PMID: 36380037
No abstract available.
3.
Kalbasi A, Siurala M, Su L, Tariveranmoshabad M, Picton L, Ravikumar P, et al.
Nature
. 2022 Jun;
607(7918):360-365.
PMID: 35676488
Synthetic receptor signalling has the potential to endow adoptively transferred T cells with new functions that overcome major barriers in the treatment of solid tumours, including the need for conditioning...
4.
Singh N, Frey N, Engels B, Barrett D, Shestova O, Ravikumar P, et al.
Nat Med
. 2021 Apr;
27(5):842-850.
PMID: 33888899
While CD19-directed chimeric antigen receptor (CAR) T cells can induce remission in patients with B cell acute lymphoblastic leukemia (ALL), a large subset relapse with CD19 disease. Like CD19, CD22...
5.
Oda S, Anderson K, Ravikumar P, Bonson P, Garcia N, Jenkins C, et al.
J Exp Med
. 2020 Aug;
217(12).
PMID: 32860705
Adoptive T cell therapy (ACT) with genetically modified T cells has shown impressive results against some hematologic cancers, but efficacy in solid tumors can be limited by restrictive tumor microenvironments...
6.
Singh N, Lee Y, Shestova O, Ravikumar P, Hayer K, Hong S, et al.
Cancer Discov
. 2020 Feb;
10(4):552-567.
PMID: 32001516
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy (CART19) occurs in 10% to 20% of patients with acute lymphoblastic leukemia (ALL); however, the mechanisms of this resistance remain elusive....
7.
Billingsley M, Singh N, Ravikumar P, Zhang R, June C, Mitchell M
Nano Lett
. 2020 Jan;
20(3):1578-1589.
PMID: 31951421
Chimeric antigen receptor (CAR) T cell therapy relies on the manipulation of patient T cells to create potent, cancer-targeting therapies, shown to be capable of inducing remission in patients with...
8.
Subathra Devi C, Verma P, Srivastava S, Ravikumar P, Kalwani V, Tandon A, et al.
Curr Drug Discov Technol
. 2014 Nov;
11(4):239-42.
PMID: 25373791
P. falciparum is highly virulent in nature because of its ability to modify the infected host red blood cells, adherence to the vascular endothelium and changes in antigenicity at different...